ArticleRSC advances2026

Targeting DYRK1A with rationally designed pyrazine-guanidine hybrids for Alzheimer's disease: design, synthesis, and biological evaluation.

Sabiha Khan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.